Canaccord raised the firm’s price target on Seres Therapeutics (MCRB) to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres’ proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions while also noting Seres is reducing staff by 25%, including August 2025 reductions, which should provide sufficient cash to fund operations into 2Q26.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics announces further constructive feedback from FDA on SER-155
- Seres Therapeutics’ Earnings Call: Progress Amid Challenges
- Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics
- Seres Therapeutics Reports Q2 2025 Financial Results
- Seres Therapeutics Reports Q2 Results and Leadership Change